Drug-Induced Lung Disease (Organizing Pneumonia) Associated with Mesalazine
https://doi.org/10.21292/2075-1230-2022-100-1-55-60
Abstract
The article describes a clinical case of mesalazine-related lung disease in a patient treated for ulcerative colitis.
About the Authors
E. V. Smirnova
Vinogradov City Clinical Hospital
Russian Federation
Russian Federation
Elena V. Smirnova - Candidate of Medical Sciences, General Practitioner
Phone: +7 (495) 103-46-66
61, Vavilov St., Moscow, 117292
D. A. Strelkova
RUDN University
Russian Federation
Russian Federation
Darya A. Strelkova - Resident of Internal Diseases Department with Training in Cardiology and Functional Diagnostics named after V.S. Moiseev
Phone: +7 (495) 434-53-00
6, Miklukho-Maklaya St., Moscow, 117198
S. A. Ratchina
I. M. Sechenov First Moscow State Medical University (Sechenov University),
Russian Federation
Russian Federation
Svetlana A. Ratchina - Doctor of Medical Sciences, Head of Hospital Therapy Department no. 2 of General Medicine Faculty
Phone: +7 (499) 248-01-81
4, Bd. 2, Bolshaya Pirogovskaya St., Moscow, 119991
S. N. Avdeev
I. M. Sechenov First Moscow State Medical University (Sechenov University),
Russian Federation
Russian Federation
Sergey N. Avdeev - Doctor of Medical Sciences, Professor, Correspondent Member of RAS, Head of Pulmonology Department of General Medicine Faculty
Phone: + 7 (495) 708-35-76
4, Bd. 2, Bolshaya Pirogovskaya St., Moscow, 119991
O. V. Aryutina
Vinogradov City Clinical Hospital
Russian Federation
Russian Federation
Olga V. Aryutina - Head of X-Ray Department
Phone: +7 (495) 103-46-66
61, Vavilov St., Moscow, 117292
O. Yu. Karpova
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Olga Yu. Karpova - Candidate of Medical Sciences, Associate Professor of Hospital Therapy Department no. 2 of General Medicine Faculty
Phone: +7 (499) 248-01-81
4, Bd. 2, Bolshaya Pirogovskaya St., Moscow, 119991
References
1. Аvdeev S.N., Chernyaev А.L., Chuchalin А.G. Organizing pneumonia: diagnostics, symptoms and treatment. Terapevt. Arkh., 2012, vol. 84, no. 3, pp. 38-44. (In Russ.)
2. Ivashkin V.T., Shelygin Yu.А., Khalif I.L., Belousova E.А., Shifrin O.S., Аbdulganieva D.I., Аbdulkhakov R.А. et al. Guidelines of the Russian Gastroenterological Association and the Russian Association of Coloproctologists for the diagnosis and treatment of Crohn's disease. Koloproktologiya, 2017, vol. 2, no. 60, pp. 7-29. (In Russ.)
3. Ananthakrishnan A.N., Attila T., Otterson M.F., Lipchik R.J., Massey B.T., Komorowski R.A., Binion D.G. Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease. J. Clin. Gastroenterol., 2007, vol. 41, no. 7, pp. 682-688.
4. Bachmann O., Länger F., Rademacher J. Pulmonary manifestations of inflammatory bowel disease. Internist, 2010, vol. 5, no. 1, pp. 264-268.
5. Basseri B., Enayati P., Marchevsky A., Papadakis K.A. Pulmonary manifestations of inflammatory bowel disease: case presentations and review. J. Crohns Colitis, 2010, vol. 4, pp. 390-397.
6. Ceyhan B.B., Karakurt S., Cevik H., Sungur M. Bronchial hyperreactivity and allergic status in inflammatory bowel disease. Respiration, 2003, vol. 70, pp. 60-66.
7. Ekbom A., Brandt L., Granath F., Löfdahl C.G., Egesten A. Increased risk of both ulcerative colitis and Crohn's disease in a population suffering from COPD. Lung, 2008, vol. 186, no. 3, pp. 167-172.
8. Fayaz M., Sultan A., Nawaz M., Sultan N. Mesalazine-induced eosinophilic variant of Wegener`s granulomatosis in an ulcerative colitis patient. J. Ayub. Med. Coll. Abbottabad., 2009, vol. 21, no. 4, pp. 171-173.
9. Foster R.A., Zander D.S., Mergo P.J., Valentine J.F. Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestations. Inflamm. Bowel. Dis., 2003, vol. 9, no. 5, pp. 308-315.
10. Harbord M., Annese V., Vavricka S.R., Allez M., Barreiro-de Acosta M., Boberg K.M., Burisch J., De Vos M., De Vries A.M., Dick A.D., Juillerat P., Karlsen T.H., Koutroubakis I., Lakatos P.L., Orchard T., Papay P., Raine T., Reinshagen M., Thaci D., Tilg H., Carbonnel F. European Crohn’s and Colitis Organisation. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J. Crohns Colitis, 2016, vol. 10, no. 3, pp. 239-254.
11. Ji X.Q., Wang L.X., Lu D.G. Pulmonary manifestations of inflammatory bowel disease. World J. Gastroenterol., 2014, vol. 20, no. 37, pp. 13501-13511.
12. Karadag F., Ozhan M.H., Akçiçek E., Günel Ö., Alper H., Veral A. Is it possible to detect ulcerative colitis-related respiratory syndrome early? Respirology, 2001, vol. 6, pp. 341-346.
13. Majewski S., Piotrowski W. Pulmonary manifestations of inflammatory bowel disease. Arch. Med. Sci., 2015, vol. 11, no. 6, pp. 1179-1188.
14. Margagnoni G., Papi V., Aratari A., Triolo L., Papi C. Methotrexate-induced pneumonitis in a patient with Crohn's disease. J. Crohns Colitis, 2010, vol. 4, no. 2, pp. 211-214.
15. Michy B., Raymond S., Graffin B. Organizing pneumonia during treatment with mesalazine. Rev. Mal. Respir., 2014, vol. 31, pp. 70-77.
16. Moeser A., Pletz M.W., Hagel S., Kroegel C., Stallmach A. Lung disease und ulcerative colitis – mesalazine-induced bronchiolitis obliterans with organizing pneumonia or pulmonary manifestation of inflammatory bowel disease? Z. Gastroenterol., 2015, vol. 53, no. 9, pp. 1091-1098.
17. Nagy F., Molnar T., Makula E., Kiss I., Milassin P., Zollei E., Tiszlavicz L., Lonovics J. A case of interstitial pneumonitis in a patient with ulcerative colitis treated with azathioprine. World J. Gastroenterol., 2007, vol. 13, no. 2, pp. 316-319.
18. Papanikolaou I., Kagouridis K., Papiris S.A. Patterns of airway involvement in inflammatory bowel diseases. World J. Gastrointest. Pathophysiol., 2014, vol. 5, no. 4, pp. 560-569.
19. Parry S.D., Barbatzas C., Peel E.T., Barton J.R. Sulphasalazine and lung toxicity. Eur. Respir. J., 2002, vol. 19, no. 4, pp. 756-764.
20. Pereira M.R., Araujo M.J., Aguiar F.L., Lages J.V., Vieira A.L., Cruz J.F. Pulmonary toxicity to mesalazine. Eur. Respir. J., 2018, vol. 52, PA3027. doi: 10.1183/13993003.congress-2018.PA3027.
21. Sehgal P., Colombel J.F., Aboubakr A., Narula N. Systematic review: safety of mesalazine in ulcerative colitis. Aliment. Pharmacol. Ther., 2018, vol. 47, no. 12, pp. 1597-1609.
22. Songür N., Songür Y., Tüzün M., Doğan I., Tüzün D., Ensari A., Hekimoglu B. Pulmonary function tests and high-resolution CT in the detection of pulmonary involvement in inflammatory bowel disease. J. Clin. Gastroenterol., 2003, vol. 37, no. 4, pp. 292-298.
23. Villeneuve E., St-Pierre A., Haraoui B. Interstitial pneumonitis associated with infliximab therapy. J. Rheumatol., 2006, vol. 33, pp. 1189-1193.
Review
For citations:
Smirnova E.V., Strelkova D.A., Ratchina S.A., Avdeev S.N., Aryutina O.V., Karpova O.Yu. Drug-Induced Lung Disease (Organizing Pneumonia) Associated with Mesalazine. Tuberculosis and Lung Diseases. 2022;100(1):55-60. (In Russ.) https://doi.org/10.21292/2075-1230-2022-100-1-55-60
Views:
910
Email this article 